Cargando…
Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
Autores principales: | Legault, Kimberly, Blostein, Mark, Carrier, Marc, Kahn, Susan, Schulman, Sam, Shivakumar, Sudeep, Wu, Cynthia, Crowther, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236369/ https://www.ncbi.nlm.nih.gov/pubmed/32477586 http://dx.doi.org/10.1186/s40814-020-00614-0 |
Ejemplares similares
-
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
por: Legault, Kimberly, et al.
Publicado: (2020) -
Correction to: Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020) -
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015) -
MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial
por: Galanaud, Jean Philippe, et al.
Publicado: (2021) -
Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure
por: Granowicz, Eric, et al.
Publicado: (2018)